Quick Answer
PALVELLA THERAPEUTICS, INC. reported Total Revenue of $42.81 million for fiscal year 2023.
PALVELLA THERAPEUTICS, INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | $42.81M +65.3% |
$25.90M -17.6% |
$31.42M +7.1% |
$29.32M -36.6% |
| Net Income | -$41.72M -139.3% |
-$17.43M -193.3% |
$18.69M +156.2% |
-$33.28M +27.2% |
-$45.74M -22.9% |
-$37.23M -46.2% |
| Diluted EPS | -$3.71 +52.6% |
-$7.83 -460.8% |
$2.17 | — | -$0.71 -4.4% |
-$0.68 |
| Total Assets | $59.56M -32.5% |
$88.23M +1069.0% |
$7.55M -92.1% |
$95.49M -37.8% |
$153.56M +46.2% |
$105.01M -25.6% |
| Cash and Equivalents | $57.98M -30.6% |
$83.60M +1037.4% |
$7.35M -81.0% |
$38.63M -67.2% |
$117.76M +67.2% |
$70.44M +13.1% |
| Stockholders Equity | $27.98M -55.3% |
$62.61M +184.1% |
-$74.48M +20.6% |
-$93.78M -284.8% |
$50.76M +63.6% |
$31.03M -39.6% |
| R&D Expense | $22.84M +180.2% |
$8.15M -7.3% |
$8.79M -83.4% |
$52.98M -20.5% |
$66.66M +43.3% |
$46.53M -15.4% |
| Operating Income | -$38.60M -173.9% |
-$14.10M -18.8% |
-$11.87M +72.7% |
-$43.47M +16.1% |
-$51.83M -52.8% |
-$33.92M -24.9% |
| Shares Outstanding | 12.38M +12.4% |
11.01M +522.1% |
1.77M -97.6% |
74.52M +3.2% |
72.22M +29.0% |
56.00M +1.4% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2024 | $0.00 | -100.0% | — |
| Net Income | September 30, 2025 | -$11.35M | -67.5% | -19.8% |
| Diluted EPS | September 30, 2025 | -$1.03 | +73.9% | -19.8% |
| Total Assets | September 30, 2025 | $66.94M | +226.2% | -9.2% |
| Cash and Equivalents | September 30, 2025 | $63.57M | +228.3% | -9.7% |
| Stockholders Equity | September 30, 2025 | $38.68M | +144.3% | -19.0% |
| R&D Expense | September 30, 2025 | $6.53M | +105.2% | +27.5% |
| Operating Income | September 30, 2025 | -$10.18M | -101.0% | -10.0% |
| Shares Outstanding | September 30, 2025 | 11.09M | — | +0.3% |
- PALVELLA THERAPEUTICS, INC. reported Total Revenue of $42.81 million for fiscal year 2023.
- PALVELLA THERAPEUTICS, INC. showed an increase of +65.3% in Total Revenue compared to the prior fiscal year.
- PALVELLA THERAPEUTICS, INC. reported Net Income of -$41.72 million for fiscal year 2025.
- PALVELLA THERAPEUTICS, INC. showed a decrease of -139.3% in Net Income compared to the prior fiscal year.
- PALVELLA THERAPEUTICS, INC. reported Diluted EPS of $3.71 per share (loss) for fiscal year 2025.
- PALVELLA THERAPEUTICS, INC. showed an increase of +52.6% in Diluted EPS compared to the prior fiscal year.
- PALVELLA THERAPEUTICS, INC. reported Total Assets of $59.56 million for fiscal year 2025.
- PALVELLA THERAPEUTICS, INC. showed a decrease of -32.5% in Total Assets compared to the prior fiscal year.
- PALVELLA THERAPEUTICS, INC. reported Cash and Equivalents of $57.98 million for fiscal year 2025.
- PALVELLA THERAPEUTICS, INC. showed a decrease of -30.6% in Cash and Equivalents compared to the prior fiscal year.
- PALVELLA THERAPEUTICS, INC. reported Stockholders Equity of $27.98 million for fiscal year 2025.
- PALVELLA THERAPEUTICS, INC. showed a decrease of -55.3% in Stockholders Equity compared to the prior fiscal year.
- PALVELLA THERAPEUTICS, INC. reported R&D Expense of $22.84 million for fiscal year 2025.
- PALVELLA THERAPEUTICS, INC. showed an increase of +180.2% in R&D Expense compared to the prior fiscal year.
- PALVELLA THERAPEUTICS, INC. reported Operating Income of -$38.60 million for fiscal year 2025.
- PALVELLA THERAPEUTICS, INC. showed a decrease of -173.9% in Operating Income compared to the prior fiscal year.
- PALVELLA THERAPEUTICS, INC. reported Shares Outstanding of 12.38 million shares for fiscal year 2025.
- PALVELLA THERAPEUTICS, INC. showed an increase of +12.4% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: